Novavax announces COVID-19 vaccine supply deal with Serum Institute
![Novavax signs Covid-19 vaccine supply deal with Indias Serum Institute. (AFP Photo) Novavax signs Covid-19 vaccine supply deal with Indias Serum Institute. (AFP Photo)](https://s3.ap-southeast-1.amazonaws.com/images.asianage.com/images/aa-Cover-qo4lkc94037m2ug36rq5r9q8a6-20200806101607.Medi.jpeg)
Novavax Inc said on Wednesday it has entered a supply and license agreement with the Serum Institute of India for the development and commercialization of its COVID-19 vaccine candidate.
The Indian drugmaker will have exclusive rights for the vaccine in India during the term of the deal and non-exclusive rights during the “Pandemic Period” in all countries other than those designated by the World Bank as upper-middle or high-income countries.
The deal was signed on July 30, according to an SEC filing by Novavax.
On Tuesday, Novavax reported that its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus in a small, early-stage clinical trial, and that it could start a large pivotal Phase III trial as soon as late September.